Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus.
Shaik Mohammad NaushadTajamul HussainSalman A AlrokayanVijay Kumar KutalaPublished in: Pharmacological reports : PR (2022)
CYP2C9, SLCO1B1, and MTNR1B genotyping help in optimizing nateglinide therapy based on this algorithm and ensuring safety and efficacy.